Moreover, gene-modified MSCs also showed further benefits in LPS-induced sepsis and ALI treatment than did native MSCs alone, including overexpressing β-catenin, KGF, HGF, IL-10, the E-prostanoid 2 receptor, CXCR4 receptor, soluble IL-1 receptor-like-1 (sST2), ACE2, TGFβ1, CXCR7, LL-37, heme oxygenase-1, angiotensin II type 2 receptor (AT2R), Miro1, and 7ND (dominant-negative inhibitor of CCL2) (114, 115, 136–148) (Table 2). This evidence concerns the gene FGF7 and Sepsis.